Avalon GloboCare gets new Nasdaq notice over minimum equity breach

Rhea-AI Filing Summary

Avalon GloboCare Corp. reported that Nasdaq has again found it out of compliance with the Nasdaq Capital Market’s continued listing standards due to low stockholders’ equity and related criteria. Nasdaq previously notified the company that its stockholders’ equity was a deficit of $3,891,270 as of the quarter ended March 31, 2025, below the required minimum equity of $2,500,000, and that it did not meet alternative market value or net income standards.

Nasdaq had granted Avalon GloboCare up to 180 days from May 22, 2025, through November 18, 2025, to regain compliance. On November 19, 2025, Nasdaq sent a new notice stating the company remains non‑compliant and that its common stock is subject to suspension and delisting unless it requests a hearing. Avalon GloboCare plans to request a hearing before a Nasdaq Hearings Panel, which will automatically stay any suspension or delisting while the hearing process and any Panel‑granted extension period are ongoing.

Positive

• None.

Negative

• Nasdaq non-compliance and delisting risk: Avalon GloboCare remains below Nasdaq’s minimum stockholders’ equity requirement of $2,500,000, after reporting a deficit of $3,891,270 as of March 31, 2025, prompting a new Nasdaq notice that its common stock is subject to suspension and delisting absent a successful hearing process.

Insights

Equity & Listing Standards Analyst

Nasdaq has moved Avalon GloboCare closer to delisting over equity deficits.

Nasdaq determined that Avalon GloboCare failed to meet the Nasdaq Capital Market’s minimum stockholders’ equity requirement of $2,500,000. The company instead reported negative stockholders’ equity of $3,891,270 as of the quarter ended March 31, 2025, and did not qualify under alternative market value or net income tests. An earlier compliance plan earned a 180‑day extension through November 18, 2025, but the company did not regain compliance by that date.

The new Nasdaq notice dated November 19, 2025 states that the company’s common stock is now subject to suspension and delisting unless it requests a hearing. Avalon GloboCare plans to seek that hearing, which will automatically stay suspension and delisting during the hearing process and any additional extension period granted by the Panel. The company’s future listing status will hinge on its ability to meet Nasdaq’s financial criteria or secure an acceptable remediation plan through this process.

false 0001630212 0001630212 2025-11-19 2025-11-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 19, 2025

AVALON GLOBOCARE CORP.

(Exact name of registrant as specified in its charter)

Delaware		001-38728		47-1685128
(State or other jurisdiction		(Commission File Number)		(I.R.S. Employer
of incorporation)				Identification Number)

4400 Route 9 South, Suite 3100, Freehold, NJ 07728

(Address of principal executive offices)

(732) 780-4400

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.)

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ALBT		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, on May 22, 2025, Avalon GloboCare Corp. (the “Company”) received a letter (the “May Nasdaq Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, under Listing Rule 5550(b)(1), because the Company’s stockholders’ equity of ($3,891,270), as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2025, was below the required minimum of $2,500,000, and because, as of May 22, 2025, the Company did not meet the alternative compliance standards, relating to the market value of listed securities of $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years.

The May Nasdaq Letter had no immediate impact on the listing of the Company’s common stock, which continued to be listed and traded on The Nasdaq Capital Market, subject to the Company’s compliance with the other continued listing requirements. Following the Company’s submission of a plan to regain compliance with Listing Rule 5550(b)(1), Nasdaq granted the Company an extension of up to 180 calendar days from May 22, 2025, or through November 18, 2025, to regain compliance.

On November 19, 2025, the Company received a letter (the “November Nasdaq Letter”) from Nasdaq indicating that the Company was not in compliance with Listing Rule 5550(b). Unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”), trading of the Company’s common stock would be subject to suspension/delisting. Accordingly, the Company plans to timely request a hearing before the Panel, which request will automatically stay any suspension or delisting action by Nasdaq pending the hearing and the expiration of any additional extension period granted by the Panel following the hearing.

The Company, by filing this Current Report on Form 8-K, discloses its receipt of the notification from Nasdaq in accordance with Listing Rule 5810(b).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AVALON GLOBOCARE CORP.
Dated: November 21, 2025	By:	/s/ Luisa Ingargiola
	Name:	Luisa Ingargiola
	Title:	Chief Financial Officer

FAQ

Why did Nasdaq notify Avalon GloboCare (ALBT) of potential delisting?

Nasdaq notified Avalon GloboCare because it failed to meet the minimum stockholders’ equity requirement under Listing Rule 5550(b)(1) and did not qualify under alternative market value or net income standards.

What was Avalon GloboCares reported stockholders equity that led to the Nasdaq issue?

Avalon GloboCare reported stockholders equity of ($3,891,270), a deficit, in its Form 10-Q for the quarter ended March 31, 2025, compared with Nasdaqs required minimum equity of $2,500,000.

What compliance extension did Nasdaq previously grant Avalon GloboCare (ALBT)?

After Avalon GloboCare submitted a plan to regain compliance, Nasdaq granted an extension of up to 180 calendar days from May 22, 2025, through November 18, 2025, to meet Listing Rule 5550(b)(1).

What does the November 19, 2025 Nasdaq letter mean for Avalon GloboCares listing?

The November 19, 2025 letter states Avalon GloboCare is not in compliance with Listing Rule 5550(b) and that trading in its common stock is subject to suspension and delisting unless it timely requests a hearing before a Nasdaq Hearings Panel.

How is Avalon GloboCare responding to Nasdaqs latest delisting notice?

Avalon GloboCare plans to timely request a hearing before a Nasdaq Hearings Panel, which will automatically stay any suspension or delisting action while the hearing and any Panel-granted extension period are pending.

Will Avalon GloboCare (ALBT) be immediately delisted from Nasdaq?

No immediate delisting is described; Avalon GloboCare intends to request a hearing, and that request will automatically stay suspension or delisting while the hearing process and any extension period granted by the Panel are in effect.